Glioblastoma: imaging genomic mapping reveals sex-specific oncogenic associations of cell death.

PURPOSE To identify the molecular profiles of cell death as defined by necrosis volumes at magnetic resonance (MR) imaging and uncover sex-specific molecular signatures potentially driving oncogenesis and cell death in glioblastoma (GBM). MATERIALS AND METHODS This retrospective study was HIPAA compliant and had institutional review board approval, with waiver of the need to obtain informed consent. The molecular profiles for 99 patients (30 female patients, 69 male patients) were identified from the Cancer Genome Atlas, and quantitative MR imaging data were obtained from the Cancer Imaging Archive. Volumes of necrosis at MR imaging were extracted. Differential gene expression profiles were obtained in those patients (including male and female patients separately) with high versus low MR imaging volumes of tumor necrosis. Ingenuity Pathway Analysis was used for messenger RNA-microRNA interaction analysis. A histopathologic data set (n = 368; 144 female patients, 224 male patients) was used to validate the MR imaging findings by assessing the amount of cell death. A connectivity map was used to identify therapeutic agents potentially targeting sex-specific cell death in GBM. RESULTS Female patients showed significantly lower volumes of necrosis at MR imaging than male patients (6821 vs 11 050 mm(3), P = .03). Female patients, unlike male patients, with high volumes of necrosis at imaging had significantly shorter survival (6.5 vs 14.5 months, P = .01). Transcription factor analysis suggested that cell death in female patients with GBM is associated with MYC, while that in male patients is associated with TP53 activity. Additionally, a group of therapeutic agents that can potentially be tested to target cell death in a sex-specific manner was identified. CONCLUSION The results of this study suggest that cell death in GBM may be driven by sex-specific molecular pathways.

[1]  K. Srivenugopal,et al.  The MDM2-p53 pathway revisited , 2013, Journal of biomedical research.

[2]  David Gutman,et al.  Genomic mapping and survival prediction in glioblastoma: molecular subclassification strengthened by hemodynamic imaging biomarkers. , 2013, Radiology.

[3]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.

[4]  F Giangaspero,et al.  Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. , 1983, Journal of neurosurgery.

[5]  Chi V. Dang,et al.  c-Myc Target Genes Involved in Cell Growth, Apoptosis, and Metabolism , 1999, Molecular and Cellular Biology.

[6]  W. Malorni,et al.  Sex differences at cellular level: "cells have a sex". , 2012, Handbook of experimental pharmacology.

[7]  Margaret Wrensch,et al.  Epidemiology and molecular pathology of glioma , 2006, Nature Clinical Practice Neurology.

[8]  Paul S Mischel,et al.  Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis. , 2008, Radiology.

[9]  Paul A Clemons,et al.  The Connectivity Map: Using Gene-Expression Signatures to Connect Small Molecules, Genes, and Disease , 2006, Science.

[10]  L. Rorke Anatomical Features of the Developing Brain Implicated in Pathogenesis of Hypoxic‐Ischemic Injury , 1992, Brain pathology.

[11]  P. Laurent-Puig,et al.  Gender-specific profiling in SCN1A polymorphisms and time-to-recurrence in patients with stage II/III colorectal cancer treated with adjuvant 5-fluoruracil chemotherapy , 2013, The Pharmacogenomics Journal.

[12]  P. Carmeliet,et al.  Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis , 1998, Nature.

[13]  Raymond Sawaya,et al.  Prognostic significance of preoperative MRI scans in glioblastoma multiforme , 2004, Journal of Neuro-Oncology.

[14]  Ferenc A. Jolesz,et al.  Radiogenomic Mapping of Edema/Cellular Invasion MRI-Phenotypes in Glioblastoma Multiforme , 2011, PloS one.

[15]  G. Atwal,et al.  An Information-Theoretic Analysis of Genetics, Gender and Age in Cancer Patients , 2008, PloS one.

[16]  S. Lowe,et al.  Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants , 2005, Nature.

[17]  K. Vousden,et al.  p53 mutations in cancer , 2013, Nature Cell Biology.

[18]  Paola Pisani,et al.  Genetic Pathways to Glioblastoma , 2004, Cancer Research.

[19]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[20]  William D. Dunn,et al.  MR imaging predictors of molecular profile and survival: multi-institutional study of the TCGA glioblastoma data set. , 2013, Radiology.

[21]  Georg Breier,et al.  Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo , 1992, Nature.

[22]  H. Lenz,et al.  Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin. , 2011, Pharmacogenomics.

[23]  C. Schmidt Why do tumors become resistant to antiangiogenesis drugs? , 2009, Journal of the National Cancer Institute.

[24]  E. Zalckvar,et al.  Systems biology analysis of programmed cell death. , 2010, Trends in biochemical sciences.

[25]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[26]  Peter Vaupel,et al.  Tumor microenvironmental physiology and its implications for radiation oncology. , 2004, Seminars in radiation oncology.

[27]  Joana M. Xavier,et al.  Targeting the p53 pathway of apoptosis. , 2010, Current pharmaceutical design.

[28]  G. Morgan,et al.  Gender Disparities in the Tumor Genetics and Clinical Outcome of Multiple Myeloma , 2011, Cancer Epidemiology, Biomarkers & Prevention.

[29]  David E. Housman,et al.  Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours , 1996, Nature.

[30]  L. Ouyang,et al.  Programmed cell death pathways in cancer: a review of apoptosis, autophagy and programmed necrosis , 2012, Cell proliferation.

[31]  Rivka R Colen,et al.  Imaging genomic mapping in glioblastoma. , 2013, Neurosurgery.

[32]  Jill P. Mesirov,et al.  Comparative gene marker selection suite , 2006, Bioinform..

[33]  N. Hata,et al.  An integrated visualization system for surgical planning and guidance using image fusion and an open MR , 2001, Journal of magnetic resonance imaging : JMRI.

[34]  Joel H. Saltz,et al.  Integrative, Multimodal Analysis of Glioblastoma Using TCGA Molecular Data, Pathology Images, and Clinical Outcomes , 2011, IEEE Transactions on Biomedical Engineering.

[35]  Xinbin Chen,et al.  p53, a Target of Estrogen Receptor (ER) α, Modulates DNA Damage-induced Growth Suppression in ER-positive Breast Cancer Cells* , 2012, The Journal of Biological Chemistry.

[36]  T. Golub,et al.  Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. , 2006, Cancer cell.

[37]  C. Schnell,et al.  PI3K inhibitors for cancer treatment: where do we stand? , 2009, Biochemical Society transactions.

[38]  Ferenc A Jolesz,et al.  A validation framework for brain tumor segmentation. , 2007, Academic radiology.

[39]  R. Johnstone,et al.  Oncogenes in cell survival and cell death. , 2012, Cold Spring Harbor perspectives in biology.

[40]  Tanja Woyke,et al.  Gene expression profile of glioblastoma multiforme invasive phenotype points to new therapeutic targets. , 2005, Neoplasia.

[41]  Joana M. Xavier,et al.  The role of p53 in apoptosis. , 2010, Discovery medicine.

[42]  K. Aldape,et al.  Identification of noninvasive imaging surrogates for brain tumor gene-expression modules , 2008, Proceedings of the National Academy of Sciences.

[43]  P. Brown,et al.  Estrogen induces c-myc gene expression via an upstream enhancer activated by the estrogen receptor and the AP-1 transcription factor. , 2011, Molecular endocrinology.

[44]  Justin Lamb,et al.  The Connectivity Map: a new tool for biomedical research , 2007, Nature Reviews Cancer.

[45]  R. Hotchkiss,et al.  Cell death. , 2009, The New England journal of medicine.

[46]  Ron Kikinis,et al.  A statistically based flow for image segmentation , 2004, Medical Image Anal..

[47]  D. Gillespie,et al.  Hypoxia‐regulated protein expression, patient characteristics, and preoperative imaging as predictors of survival in adults with glioblastoma multiforme , 2008, Cancer.

[48]  Conrad Kunick,et al.  Alsterpaullone, a novel cyclin‐dependent kinase inhibitor, induces apoptosis by activation of caspase‐9 due to perturbation in mitochondrial membrane potential , 2003, Molecular carcinogenesis.

[49]  Pascal O. Zinn,et al.  A Novel Volume-Age-KPS (VAK) Glioblastoma Classification Identifies a Prognostic Cognate microRNA-Gene Signature , 2012, PloS one.

[50]  S. Lowe,et al.  Intrinsic tumour suppression , 2004, Nature.

[51]  G. Sangiorgi,et al.  Gender‐specific aspects in the clinical presentation of cardiovascular disease , 2010, Fundamental & clinical pharmacology.

[52]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[53]  Peter T. Nelson,et al.  Hypoxia Is Important in the Biology and Aggression of Human Glial Brain Tumors , 2004, Clinical Cancer Research.